Phio Pharmaceuticals (PHIO) Other Non-Current Assets (2012 - 2024)
Phio Pharmaceuticals' (PHIO) quarterly Other Non-Current Assets came in at $3000.0 in Q2 2024, down 94.0% YoY from $50000.0 in Q3 2023, and little changed on a QoQ basis from $3000.0 in Q1 2024.
Phio Pharmaceuticals (PHIO) Other Non-Current Assets (2012 - 2024) Analysis & Trends
Phio Pharmaceuticals (PHIO) has 13 years of Other Non-Current Assets data on file, last reported at $3000.0 in Q2 2024.
- Quarterly Other Non-Current Assets fell 94.0% year-over-year to $3000.0 in Q2 2024, while the trailing twelve-month figure through Jun 2024 was $3000.0 (down 94.0% YoY) and the FY2023 annual result came in at $3000.0, down 94.0% from the prior year.
- Other Non-Current Assets was little changed at $3000.0 in Q2 2024, from $3000.0 in the prior quarter.
- In the past five years, Other Non-Current Assets ranged from a high of $50000.0 in Q2 2020 to a low of $3000.0 in Q3 2023.
- A 5-year average of $31777.8 and a median of $50000.0 in 2020 frame the typical range for Other Non-Current Assets.
- Annual changes were most pronounced in 2020 — Other Non-Current Assets jumped 177.78% — and 2023, when it tumbled 94.0%.
- Tracing PHIO's Other Non-Current Assets over 5 years: stood at $18000.0 in 2020, then jumped by 177.78% to $50000.0 in 2021, then changed by 0.0% to $50000.0 in 2022, then plunged by 94.0% to $3000.0 in 2023, then changed by 0.0% to $3000.0 in 2024.
- The last three Other Non-Current Assets figures came in at $3000.0 (Q2 2024), $3000.0 (Q1 2024), and $3000.0 (Q4 2023), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Other Non-Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | 1.25 Bn |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | 2.31 Bn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | 124.00 Mn |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | 618.00 Mn |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 109.58 Mn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | 65.13 Mn |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | 104.44 Mn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | 62.96 Mn |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | 202.31 Mn |
| 10 | Phio Pharmaceuticals | 14.06 Mn | 14.06 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2024 | 3,000.00 |
| Mar 31, 2024 | 3,000.00 |
| Dec 31, 2023 | 3,000.00 |
| Sep 30, 2023 | 3,000.00 |
| Jun 30, 2023 | 50,000.00 |
| Mar 31, 2023 | 6,000.00 |
| Dec 31, 2022 | 50,000.00 |
| Sep 30, 2022 | 50,000.00 |
| Jun 30, 2022 | 50,000.00 |
| Mar 31, 2022 | 50,000.00 |
| Dec 31, 2021 | 50,000.00 |
| Sep 30, 2021 | 50,000.00 |
| Jun 30, 2021 | 50,000.00 |
| Mar 31, 2021 | 50,000.00 |
| Dec 31, 2020 | 18,000.00 |
| Sep 30, 2020 | 18,000.00 |
| Jun 30, 2020 | 50,000.00 |
| Mar 31, 2020 | 18,000.00 |
| Dec 31, 2019 | 50,000.00 |
| Sep 30, 2019 | 18,000.00 |